Stockholm, Sweden, December 14, 2023. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced the Agenda and Registration Details for the Company’s Investor Day on Tuesday December 19, 2023, in Stockholm, Sweden, for investors, analysts and media.
 
Time: Tuesday, December 19, 2023, at 3:00 pm - 6:00 pm CET (9:00 am – 12:00 pm ET)
Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden
Registration (to attend in person): Please register by email to info@egetis.com
Webcast (no preregistration required): Please follow this link
https://www.redeye.se/events/965111/capital-markets-day-egetis-therapeutics-2
 
During the event, the Company will provide an update and review of its strategy and pipeline prospects. The presentations will focus on the Company’s drug candidate Emcitate (tiratricol) and the related unmet medical need it will address, development plans, commercial opportunities, and additional activities to create and enhance long-term shareholder value. Presentations will be made by members of Egetis’ management team, as well as invited key opinion leaders. Presentations will be held in English. The webcast will also be available on Egetis webpage www.egetis.com after the event.
 
Agenda
 

Time (CET)SubjectPresenter(s)
15:00Welcome, Corporate strategy and overviewNicklas Westerholm, CEO
15:15Development of Emcitate for MCT8 deficiency patientsWesterholm
15:30MCT8 deficiency and the unmet medical needDr Andrew Bauer, CHOP, Philadelphia, PA
15:50Q&ABauer & Westerholm
16:00Global plans for commercializing EmcitateHenrik Krook, VP Commercial
16:15Understanding MCT8 deficiency patients’ & caregivers’ needsNigel Nicholls, Global Patient Advocacy Director
16:30Improving disease awareness of MCT8 deficiencyPeter Verwaijen, Global Head of Marketing & Brand Strategy
16:45US launch preparations for EmcitateAnny Bedard, President Egetis North America
17:00Q&AKrook, Nicholls, Verwaijen, Bedard, Westerholm
17:10Break
17:30RTH-beta and the unmet medical needDr Carla Moran, University College Dublin
17:50Q&AMoran & Westerholm
18:00Concluding remarksNicklas Westerholm, CEO

 

For further information, please contact:

Nicklas Westerholm, CEO
+46 (0) 733 542 062
nicklas.westerholm@egetis.com

Karl Hård, Head of Investor Relations & Business Development
+46 (0) 733 011 944
karl.hard@egetis.com 

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company’s lead drug candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. Egetis submitted a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in October 2023.
After a dialogue with the FDA, Egetis is conducting a small randomized, placebo-controlled pivotal study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for Emcitate in mid 2024 under the Fast-Track Designation granted by FDA.
Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Emcitate has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.
The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase Iib/III study with the purpose of applying for market approval in the US and Europe for Aladote has been finalized after completed interactions with FDA, EMA and MHRA and study start is planned after Emcitate submissions have been completed. Aladote has been granted ODD in the US and in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Attachments

Egetis’ Investor Day on December 19: Agenda and Registration Details

© Modular Finance, source Nordic Press Releases